NewsBenzingaLa bande passante anticipe un BPA ajusté au T4 de 0,52 $ à 0,58 $ contre 0,51 $ estimé ; prévoit des ventes de 242,000 M$ à 247,000 M$ contre 244,022 M$ estimé. La bande passante anticipe un BPA ajusté au T4 de 0,52 $ à 0,58 $ contre 0,51 $ estimé ; prévoit des ventes de 242,000 M$ à 247,000 M$ contre 244,022 M$ estimé. Benzinga 2026.10.29 11:15 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients